Interleukin-6 inhibitor : tocilizumab

Inhibitors of interleukin-6 (IL-6) are proteins which decrease the actions of the inflammatory cytokine, IL-6. Clinically, tocilizumab is the major inhibitor of IL-6. Several other proteins with IL-6 inhibitory actions (e.g., sirukumab) are being tested in clinical trials. IL-6 inhibitors are members of a general class, biological disease-modifying anti-rheumatic drugs (bDMARDs). Unlike the conventional synthetic DMARDs (csDMARDs) which have small molecular masses, they are not classified as slow-acting anti-rheumatic drug (SAARDs) because they are considered to have more specific and rapidly developing actions